Biodesix announced strong Q1 2026 results with $25.6 million revenue, up 42% year-over-year, driven by a 29% increase in diagnostic test volumes and doubled Development Services revenue. The company improved gross margin to 84% and reduced net loss by 30%, signaling progress toward profitability. Biodesix raised its full-year 2026 revenue guidance to $108-114 million, expecting continued growth and operational leverage. This performance highlights Biodesix's expanding market presence and operational efficiency in diagnostic solutions.
CMS Energy is refocusing its business by divesting non-utility renewables to concentrate on its core regulated utility operations. In Q2 2026, the company reported earnings per share of $0.37, slightly above analyst expectations, but revenue fell sho...
Teradyne is set to report strong Q2 earnings on July 28, 2026, with Wall Street forecasting $2.09 earnings per share and $1.22 billion in revenue, reflecting significant growth fueled by AI market demand. About 70% of Teradyne's revenue now comes fro...
Nexans announced new appointments to its Board of Directors committees, naming Antonio Cammisecra to the Nominations, Remunerations, and Strategic & Sustainable Development Committees, Thierry Fournier to the Audit and Strategic & Sustainable Develop...
Nexans announced new appointments to its Board of Directors' committees, including Antonio Cammisecra joining three committees and Thierry Fournier joining two. Marc Grynberg was named Chairman of the Strategy and Sustainable Development Committee. T...
Pennant Group, a healthcare services holding company, announced it will release its second quarter 2026 financial results on August 5, 2026. The company will host a live webcast on August 6 at 10:00 a.m. Mountain Time to discuss the results. Investor...
